Loading...
Loading...
While four big companies from the pharmaceutical segment have already reported their September quarter results, a handful remain yet to report.
The following companies have reported their results for the September quarter:
- Abbott Laboratories ABT reported adjusted EPS of $0.59 on revenue of $5.3 billion. While EPS topped by a penny, revenue came in line.
- Eli Lilly and Co LLY reported adjusted EPS of $0.88, revenue of $5.19 billion and missed Street estimates.
- Merck & Co., Inc. MRK reported GAAP EPS of $0.78 and adjusted EPS of $1.07 on revenue of $10.5 billion. Both EPS and revenue topped estimates.
- Novartis AG (ADR) NVS reported core EPS of $1.23 and net sales of $12.13 billion. While EPS topped estimates, revenue fell shy of expectations.
The following companies have yet to announce September quarter results:
- AstraZeneca plc (ADR) AZN is scheduled to disclose its results on November 10. Analysts expect EPS of $0.74 on revenue of $5.91 billion.
- Bristol-Myers Squibb Co BMY is slated to provide results on Thursday. Analysts expect EPS of $0.65 on revenue of $4.79 billion.
- GlaxoSmithKline plc (ADR) GSK will announce its results on Wednesday. The Street is looking for an EPS of $0.74 on revenue of $8.86 billion.
- Pfizer Inc. PFE is scheduled to report on November 1. The Street estimates EPS of $0.62 on revenue of $13.05 billion.
- Sanofi SA (ADR) SNY announces results on Friday. Analysts expect EPS of $0.85 and revenue of $10.69 billion.
- Shire PLC (ADR) SHPG is planning to announce results on November 1. The Street is looking for an EPS of $3.20 and revenue of $3.56 billion.
Full ratings data available on Benzinga Pro.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in